---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-25-000213"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:41:34.056835+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vertex Q2 revenue $2.96B (+12% YoY); CSO Altshuler to retire Aug 2026; Bunnage to succeed

## Summary
- Q2 revenue $2.96B (+12% YoY); GAAP net income $1.0B vs loss $3.6B last yr; non-GAAP net income $1.2B vs loss $3.3B
- Reiterated FY25 revenue guidance $11.85-$12.0B; combined R&D/SG&A guidance unchanged
- CSO David Altshuler to retire Aug 1, 2026; Mark Bunnage becomes CSO effective Feb 1, 2026 as planned transition
- VX-993 Phase 2 acute pain study missed primary endpoint; Vertex not advancing it as monotherapy
- CASGEVY: ~115 patients had first cell collection, 29 infused; JOURNAVX: >110,000 prescriptions filled

## SEC filing metadata
- accession: 0000875320-25-000213
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532025000213/0000875320-25-000213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532025000213/vrtx-20250804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-25-000213
- JSON: https://secwatch.observer/filing/0000875320-25-000213.json
- Plain text: https://secwatch.observer/filing/0000875320-25-000213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.